VKTX SEC Filings, Earnings & Splits

Viking Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, confirming its status as a large accelerated filer with 127,522,189 shares of common stock outstanding.

Viking Therapeutics filed a routine Form 8-K cover page with no substantive corporate event disclosed in the provided text.

Viking Therapeutics, Inc. filed a Form 8-K on September 23, 2026, providing standard entity and filing information with no material event disclosed.

Viking Therapeutics, Inc. filed a prospectus supplement (424B5) for a secondary offering of securities under its existing S-3 shelf registration.

Viking Therapeutics, Inc. filed a 424B5 prospectus supplement for a secondary offering of securities under its existing S-3 shelf registration.

Viking Therapeutics is offering convertible senior notes due 2032, with a concurrent common stock offering. The notes will mature on October 15, 2032, and are senior unsecured obligations.

Viking Therapeutics is offering shares of its common stock in a public offering, with a concurrent offering of convertible senior notes due 2032. The offering is being underwritten by Morgan Stanley and J.P. Morgan.

Viking Therapeutics, Inc. filed an 8-K form with the SEC on September 22, 2026, providing standard corporate information and updates.